





## Dana-Farber Cancer Institute, Gustave Roussy, and L'Institut Servier sign an oncology cooperation agreement

Paris, France, Boston, United States, 7 June 2022 – L'Institut Servier, Gustave Roussy (Villejuif, France), and Dana-Farber Cancer Institute (Boston, USA) have signed a cooperation agreement to foster exchange and develop bilateral collaboration among researchers from these two renowned oncology centers.

The two-year agreement includes the organization of annual conferences, alternating between Boston and Paris, and the establishment of a fellowship program for four young researchers, post-doctoral students from Gustave Roussy, who will be hosted in research labs of Dana-Farber.

The conferences, entitled "Dana-Farber/Gustave Roussy Days in Oncology", will bring together clinical cancer researchers from the two institutes once a year. The conferences will be open to health professionals specializing in oncology (researchers, clinicians and students) and will be broadcast online on international Continuing Medical Education sites.

The first conference - *Trans-Atlantic Exchanges in Immuno-Oncology* - was held in Boston on May 13 and was dedicated to the latest advances in immuno-oncology, bringing together more than 1,700 oncology health professionals: <a href="https://www.transatlantic-i-o.com/">https://www.transatlantic-i-o.com/</a>. The second conference is planned for June 2023 in Paris.

"This is an exciting collaboration that brings together two of the world leaders in cancer research and the development of new therapies", said Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology and Medical Director of International Strategic Initiatives at Dana-Farber and Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. "As we saw during our first conference last month, we have a great deal to learn from each other and to share with our colleagues around the world as we find new ways to end cancer."

Internationally renowned, Gustave Roussy is the leading cancer center in Europe. "The high level of exchanges during our first conference perfectly reflects the challenges of our collaboration. Brightest minds will work together to identify new leads against cancer and to share the latest advances in oncology" said Prof.Fabrice Barlesi, General Director of Gustave Roussy

L'Institut Servier conceived of this collaboration and through its Scientific Committee will provide both organizational and financial support for annual conferences and fellowship program.

"We believe that fostering meetings and exchanges between researchers and clinicians from these renowned centers of scientific excellence - Dana Farber Cancer Institute and Gustave Roussy - will create synergies and bilateral collaborations promoting therapeutic innovation for the benefit of patients. This conviction is at the heart of L'Institut Servier's vocation, which is to support research, foster vocations and to promote medical knowledge in the field of Oncology in particular" said Christophe Charpentier, MD, Managing Director of L'Institut Servier.







## **About Dana-Farber Cancer Institute**

<u>Dana-Farber Cancer Institute</u> is one of the world's leading centers of cancer research and treatment. Dana-Farber's mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.

We provide the latest treatments in cancer for adults through <u>Dana-Farber Brigham Cancer Center</u> and for children through <u>Dana-Farber/Boston Children's Cancer and Blood Disorders Center</u>. Dana-Farber is the only hospital nationwide with a top 5 *U.S. News & World Report* Best Cancer Hospital ranking in both adult and pediatric care.

As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.

## **About Gustave Roussy**

Ranked as the leading European Cancer Centre and sixth in the world by Newsweek, Gustave Roussy is a center with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient's human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient's life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: a quarter of patients treated are included in clinical trials. For further information: <a href="https://www.gustaveroussy.fr/en">www.gustaveroussy.fr/en</a>, <a href="https://www.gustaveroussy.fr/en">Twitter</a>, <a href="https://www.gustaveroussy.fr/en</a>, <

## **About L'Institut Servier**

L'Institut Servier is a non-profit association. Its mission is to develop research in all its forms as well as scientific knowledge for medical progress. It does this by organizing high-level conferences and awarding grants that allow post-docs, medical students and researchers to pursue a degree outside their country of origin through partnerships with organizations dedicated to worldwide health and sponsorship of training organizations in emerging countries.

For further information: www.institut-servier.com/en, LinkedIn